IVIG Therapy Guidelines for Patients with Hypogammaglobulinemia

Introduction to IVIG Therapy

• The National Comprehensive Cancer Network (NCCN) recommends monthly 400-500 mg/kg IVIG replacement for patients with serum IgG levels <400-600 mg/dL and serious or recurrent infections 4, 3
• Expert consensus guidelines recommend IVIG therapy for patients with IgG levels <400 mg/dL, ≥2 severe recurrent infections by encapsulated bacteria, life-threatening infections, or documented bacterial infections with insufficient response to antibiotics 1, 2

Threshold for IVIG Initiation and Continuation

• The American College of Physicians and other medical societies suggest that IVIG treatment is recommended for the duration of immunoparesis until IgG levels are ≥400 mg/dL 1, 2
• Monthly monitoring of IgG levels during treatment is recommended 1, 2

Standard of Care Assessment

• IVIG therapy for hypogammaglobulinemia is considered standard of care when IgG levels are <400-600 mg/dL, patient experiences serious or recurrent bacterial infections, or patient has documented immunodeficiency with clinical manifestations 1, 4, 2, 3

Common Pitfalls and Considerations

• Serum IgG levels alone are not adequate to determine an individual's capacity to mount antibody responses; monitoring frequency of infections is equally important 1, 2
• Patients who have undergone CAR-T therapy may experience prolonged hypogammaglobulinemia, but IVIG is only indicated when levels fall below thresholds and patient experiences significant infections 4, 3
• Unnecessary continuation of IVIG therapy exposes patients to potential adverse effects including headache, aseptic meningitis, and anaphylaxis 7
• Cost-effectiveness should be considered when IgG levels are adequate and infection risk is low 5, 6